[O2] Oral Presentations 2

11:42 AM - 11:49 AM JST(2:42 AM - 2:49 AM UTC)

[O2-07] Innovative mucosal adjuvant development using heat-killed Escherichia coli

*Peng Gao¹, Naoki Morita¹, Genta Furuya¹, Keishu Takahashi¹, Mizuki Yamamoto², Ryuta Uraki^3,4,5, Maki Kiso^3,4, Mutsumi Ito^3,4, Hideo Negishi⁶, Chiaki Tomimoto⁷, Mizuho Wakayama⁷, Ken J. Ishii⁶, Yoshihiro Kawaoka^3,4, Reiko Shinkura¹ (1. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo (Japan), 2. Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan (Japan), 3. Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan (Japan), 4. Division of Virology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan (Japan), 5. The Research Center for Global Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 7. Noster Inc (Japan))

Keywords:

mucosal vaccine,IgA,adjuvant,Influenza viruses,SARS-CoV-2

Password required to view

Log in

or